Adalimumab and Anti-Adalimumab antibody

Alphabetical Test listing

Adalimumab and Anti-Adalimumab antibody-13581

  
Adalimumab and Anti-Adalimumab antibody
  
13581
  
LAB13581
  
ADAL
  
Adalimumab
Anti-TNF-alpha Drug
Adalimumab and Anti-Adalimumab antibody, DoseASSURE ADL
Humira
  

This test provides adalimumab drug concentration levels as well as the level of antiadalimumab antibodies. This test also includes serial monitoring

  

Monitor antiadalimumab therapy for individuals with Crohn's disease, inflammatory bowel disease, ulcerative colitis, rheumatoid arthritis, or other autoimmune conditions

  
Serum
  
  
2.0 mL
  
1.0 mL
Submission of the minimum volume does not allow for repeat testing
  

Immediatley following collection, mix sample by gently inverting 5 times

  
  1. Allow a minimum clotting time of 30-60 minutes
  2. Spin within two (2) hours of sample collection
  

Gold serum separator (SST) tube

  
  
2.0 mL
  
  1. Allow sample to clot
  2. Spin within two (2) hours of sample collection
  3. Transfer serum to a Transfer vial/tube with cap - 12mL (LabCorp) labelled as "serum"
  

Refrigerated (preferred) - 7 days

Ambient - 7 days

Frozen - 308 days

  
  • Plasma specimen received
  
Esoterix Endocrinology (803890) via LabCorp (503890): R-LC
  
2x/week
  
10 days
  

Electrochemiluminescence Immunoassay (ECLIA)

  

Adalimumab drug level:

Quantitation limit: <0.6 μg/mL

Results ≥0.6 μg/mL indicate detection of adalimumab.

In the presence of antiadalimumab antibody, the adalimumab drug level reflects the antibody-unbound fraction of adalimumab concentration in serum.

Antiadalimumab antibody:

Quantitation limit: <25 ng/mL

Results ≥25 ng/mL indicate detection of adalimumab antibody

Low titer: 25-100 ng/mL

Intermediate titer: 101-300 ng/mL

Hight titer: ≥301 ng/mL

  
82397
80145
  
Result 74117-3
  
03/27/2019
  
12/27/2023
  
12/20/2023